Christine R Swanson1, Yosef Berlyand1, Sharon X Xie2, Roy N Alcalay3, Lama M Chahine1, Alice S Chen-Plotkin1. 1. Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 3. Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Abstract
BACKGROUND: Development of robust plasma-based biomarkers in Parkinson's disease (PD) could lead to new approaches for identifying those at risk for PD and developing novel therapies. Here, we validate plasma apolipoprotein A1 (ApoA1) as a correlate of age at onset and motor severity in PD. METHODS: Plasma ApoA1 and high-density lipoprotein at baseline, 6 months, and 12 months were measured in 254 research volunteers (154 patients with PD and 100 normal controls) enrolled in the Parkinson's Progression Markers Initiative (PPMI) study. RESULTS: Lower baseline plasma ApoA1 levels associate with an earlier age at PD onset in early-stage, drug-naïve PPMI PD patients (P = 0.023). Moreover, lower baseline ApoA1 levels trend toward association with worse motor severity in PPMI PD patients (p = 0.080). Over 12 months of follow-up, plasma ApoA1 levels do not predict motor decline in the PPMI PD cohort. Finally, a meta-analysis of five PD cohorts encompassing >1,000 patients confirms significant association of lower plasma ApoA1 with earlier age at PD onset (P < 0.001) and greater motor severity (P < 0.001). CONCLUSIONS: Our results confirm the previously reported association of lower plasma ApoA1 levels with two clinical features suggesting poorer dopaminergic system integrity-earlier age at PD onset and greater motor severity-in early-stage, drug-naïve PD patients. This is the first report of a plasma-based biomarker evaluated in the PPMI study. Future investigations are warranted evaluating plasma ApoA1 as a longitudinal correlate of disease progression as well as investigating the potential of ApoA1 as a therapeutic target in PD.
BACKGROUND: Development of robust plasma-based biomarkers in Parkinson's disease (PD) could lead to new approaches for identifying those at risk for PD and developing novel therapies. Here, we validate plasma apolipoprotein A1 (ApoA1) as a correlate of age at onset and motor severity in PD. METHODS: Plasma ApoA1 and high-density lipoprotein at baseline, 6 months, and 12 months were measured in 254 research volunteers (154 patients with PD and 100 normal controls) enrolled in the Parkinson's Progression Markers Initiative (PPMI) study. RESULTS: Lower baseline plasma ApoA1 levels associate with an earlier age at PD onset in early-stage, drug-naïve PPMI PDpatients (P = 0.023). Moreover, lower baseline ApoA1 levels trend toward association with worse motor severity in PPMI PDpatients (p = 0.080). Over 12 months of follow-up, plasma ApoA1 levels do not predict motor decline in the PPMI PD cohort. Finally, a meta-analysis of five PD cohorts encompassing >1,000 patients confirms significant association of lower plasma ApoA1 with earlier age at PD onset (P < 0.001) and greater motor severity (P < 0.001). CONCLUSIONS: Our results confirm the previously reported association of lower plasma ApoA1 levels with two clinical features suggesting poorer dopaminergic system integrity-earlier age at PD onset and greater motor severity-in early-stage, drug-naïve PDpatients. This is the first report of a plasma-based biomarker evaluated in the PPMI study. Future investigations are warranted evaluating plasma ApoA1 as a longitudinal correlate of disease progression as well as investigating the potential of ApoA1 as a therapeutic target in PD.
Authors: Takahiko Tokuda; Sultan A Salem; David Allsop; Toshiki Mizuno; Masanori Nakagawa; Mohamed M Qureshi; Joseph J Locascio; Michael G Schlossmacher; Omar M A El-Agnaf Journal: Biochem Biophys Res Commun Date: 2006-08-14 Impact factor: 3.575
Authors: Min Shi; Joshua Bradner; Aneeka M Hancock; Kathryn A Chung; Joseph F Quinn; Elaine R Peskind; Douglas Galasko; Joseph Jankovic; Cyrus P Zabetian; Hojoong M Kim; James B Leverenz; Thomas J Montine; Carmen Ginghina; Un Jung Kang; Kevin C Cain; Yu Wang; Jan Aasly; David Goldstein; Jing Zhang Journal: Ann Neurol Date: 2011-03-11 Impact factor: 10.422
Authors: E R Dorsey; R Constantinescu; J P Thompson; K M Biglan; R G Holloway; K Kieburtz; F J Marshall; B M Ravina; G Schifitto; A Siderowf; C M Tanner Journal: Neurology Date: 2006-11-02 Impact factor: 9.910
Authors: Benjamin L Deck; Jacqueline Rick; Sharon X Xie; Alice Chen-Plotkin; John E Duda; James F Morley; Lana M Chahine; Nabila Dahodwala; John Q Trojanowski; Daniel Weintraub Journal: J Parkinsons Dis Date: 2017 Impact factor: 5.568
Authors: Katrina Gwinn; Karen K David; Christine Swanson-Fischer; Roger Albin; Coryse St Hillaire-Clarke; Beth-Anne Sieber; Codrin Lungu; F DuBois Bowman; Roy N Alcalay; Debra Babcock; Ted M Dawson; Richard B Dewey; Tatiana Foroud; Dwight German; Xuemei Huang; Vlad Petyuk; Judith A Potashkin; Rachel Saunders-Pullman; Margaret Sutherland; David R Walt; Andrew B West; Jing Zhang; Alice Chen-Plotkin; Clemens R Scherzer; David E Vaillancourt; Liana S Rosenthal Journal: Biomark Med Date: 2017-06-23 Impact factor: 2.851
Authors: Umar Yazdani; Sayed Zaman; Linda S Hynan; L Steven Brown; Richard B Dewey; David Karp; Dwight C German Journal: NPJ Parkinsons Dis Date: 2016-06-23